Sugi Predict

Sugi Predict / Compounds / SCHEMBL326687

SCHEMBL326687

SCHEMBL326687

O=[N+]([O-])c1ccc(-c2cnon2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 6/20 0.47
▸ NPC1 O15118 5/20 0.47
▸ MAPT P10636 11/20 0.46
▸ LMNA P02545 3/20 0.46
▸ APP P05067 1/20 0.43
▸ KDM4E B2RXH2 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ GAA P10253 1/20 0.42
▸ NOTUM Q6P988 1/20 0.41
▸ MEN1 O00255 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ CHRNB2 P17787 1/20 0.41
▸ CHRNA5 P30532 1/20 0.41
▸ CHRNA4 P43681 1/20 0.41
▸ POLB P06746 2/20 0.41
▸ XDH P47989 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ MCL1 Q07820 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ CA12 O43570 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27795093 0.78 CYP3A4 (0.41) RAB9ANPC1MAPTALDH1A1MEN1
Dl-Phenylalanine SCHEMBL28967804 0.78 PKM (0.48) RAB9ANPC1MEN1KMT2APKM
SCHEMBL30461131 0.75 RAB9A (0.64) RAB9ANPC1MAPTLMNAAPP
SCHEMBL5139807 0.73 MAPT (0.46) RAB9ANPC1MAPTLMNAAPP
SCHEMBL30461132 0.72 MAOB (0.54) RAB9ANPC1MAPTLMNAAPP
SCHEMBL27617094 0.72 RAB9A (0.56) RAB9ANPC1MAPTLMNAAPP
SCHEMBL30461133 0.72 RAB9A (0.60) RAB9ANPC1MAPTLMNAAPP
SCHEMBL30461134 0.72 RAB9A (0.60) RAB9ANPC1MAPTLMNAAPP
SCHEMBL4022663 0.71 NOTUM (0.44) RAB9ANPC1MAPTKDM4EALDH1A1
SCHEMBL29102300 0.71 TDO2 (0.41) RAB9ANPC1KDM4EALDH1A1NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12616759-B2 Uses of labeled HSP90 inhibitors SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2026-05-05 — — US disclosed
US-20240058482-A1 USES OF LABELED HSP90 INHIBITORS SLOAN KETTERING INST CANCER RES (US) 2024-02-22 — — US disclosed
US-11607465-B2 Uses of labeled HSP90 inhibitors SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2023-03-21 — — US disclosed
CN-115806583-A Amphiphilic polypeptide derivative and application thereof 中国药科大学 2023-03-17 — — CN disclosed
CN-113956328-A Preparation and application of polypeptide hydrogel with double enzyme responses 中国药科大学 2022-01-21 — — CN disclosed
CN-113956328-A Preparation and application of polypeptide hydrogel with double enzyme responses 中国药科大学 2022-01-21 — — CN disclosed
US-20210138091-A1 USES OF LABELED HSP90 INHIBITORS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH 2021-05-13 — — US disclosed
EP-3709022-A1 USES OF LABELED HSP90 INHIBITORS Sloan-Kettering Institute for Cancer Research (US) 2020-09-16 — — EP disclosed
EP-3208615-B1 USES OF LABELED HSP90 INHIBITORS SLOAN KETTERING INST CANCER RES (US) 2019-10-09 — — EP disclosed
EP-3208615-A2 USES OF LABELED HSP90 INHIBITORS Sloan Kettering Institute For Cancer Research (US) 2017-08-23 — — EP disclosed
EP-2729806-A1 USES OF LABELED HSP90 INHIBITORS Sloan-kettering Institute For Cancer Research (US) 2014-05-14 — — EP disclosed
US-20130178609-A1 MODULAR CONSTRUCTION OF LIPOPHOSPHOLIPIDS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) 2013-07-11 — — US disclosed
EP-2590989-A2 MODULAR CONSTRUCTION OF LIPOPHOSPHOLIPIDS Universite de Bretagne Occidentale (FR) 2013-05-15 — — EP disclosed
WO-2013009657-A1 USES OF LABELED HSP90 INHIBITORS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2013-01-17 — — WO disclosed
WO-2013009655-A2 USES OF LABELED HSP90 INHIBITORS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2013-01-17 — — WO disclosed
WO-2012004419-A2 MODULAR CONSTRUCTION OF LIPOPHOSPHOLIPIDS UNIVERSITÉ DE BRETAGNE OCCIDENTALE (FR) 2012-01-12 — — WO disclosed
EP-1315752-A4 MODIFIED PROTEINS, ISOLATED NOVEL PEPTIDES, AND USES THEREOF UNIV AUSTRALIAN (AU) 2005-07-06 — — EP disclosed
EP-1315752-A1 MODIFIED PROTEINS, ISOLATED NOVEL PEPTIDES, AND USES THEREOF THE AUSTRALIAN NATIONAL UNIVERSITY (AU) 2003-06-04 — — EP disclosed
WO-2002018438-A9 MODIFIED PROTEINS, ISOLATED NOVEL PEPTIDES, AND USES THEREOF UNIV AUSTRALIAN (AU) 2002-05-30 — — WO disclosed
WO-2002018438-A1 MODIFIED PROTEINS, ISOLATED NOVEL PEPTIDES, AND USES THEREOF THE AUSTRALIAN NATIONAL UNIVERSITY (AU) 2002-03-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240058482-A1 USES OF LABELED HSP90 INHIBITORS HSP90AB1, HSP90B1, HSP90AA1 RAB9A 2221/4885NPC1 2023/4885MAPT 3062/4885
US-20130178609-A1 MODULAR CONSTRUCTION OF LIPOPHOSPHOLIPIDS SGMS2, SGMS1, DEGS1 RAB9A 2013/4885NPC1 227/4885MAPT 4830/4885
US-12616759-B2 Uses of labeled HSP90 inhibitors HSP90AB1, HSP90B1, HSP90AB2P RAB9A 1420/4885NPC1 1077/4885MAPT 1392/4885
US-11607465-B2 Uses of labeled HSP90 inhibitors HSP90AB1, HSP90B1, HSP90AA1 RAB9A 2221/4885NPC1 2023/4885MAPT 3062/4885
US-20210138091-A1 USES OF LABELED HSP90 INHIBITORS HSP90AB1, HSP90B1, HSP90AA1 RAB9A 2221/4885NPC1 2023/4885MAPT 3062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.